Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karina Jahnz-Różyk

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Postepy Dermatologii I Alergologii|May 18, 2026
Analysis of financing of drug programs in allergology in 2020-2024Krzysztof Nojszewski, Karina Jahnz-Różyk
International Journal of Chronic Obstructive Pulmonary Disease|April 3, 2015
Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational studyKarina Jahnz-Różyk, Paweł Szepiel
Postepy Higieny I Medycyny Doswiadczalnej (Online)|June 4, 2016
[Autoimmune connective tissue diseases and vaccination]Ewa Więsik-Szewczyk, Karina Jahnz-Różyk
Medicine|November 2, 2018
A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacementEwa Więsik-Szewczyk, Karina Jahnz-Różyk
World Journal of Clinical Cases|October 7, 2020
From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiencyEwa Więsik-Szewczyk, Karina Jahnz-Różyk
Reumatologia|December 18, 2019
Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome persisting to adulthood - an example of a diagnostic and therapeutic challengeEwa Więsik-Szewczyk, Beata Wolska-Kuśnierz, Karina Jahnz-Różyk
BMC Pulmonary Medicine|March 18, 2018
Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in PolandKarina Jahnz-Różyk, Joanna Lis, Marta Warchoł, et al.
Value in Health Regional Issues|October 28, 2017
Drug Policy in PolandKarina Jahnz-Różyk, Pawel Kawalec, Krzysztof Malinowski, et al.
Frontiers in Immunology|May 20, 2026
Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimizationMariusz Sikora, Marcin Ziętkiewicz, Karina Jahnz-Różyk, et al.
Journal of Asthma and Allergy|December 28, 2020
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life ObservationAleksandra Kucharczyk, Ewa Więsik-Szewczyk, Anna Poznańska, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Postepy Dermatologii I Alergologii|May 18, 2026
Analysis of financing of drug programs in allergology in 2020-2024Krzysztof Nojszewski, Karina Jahnz-Różyk
International Journal of Chronic Obstructive Pulmonary Disease|April 3, 2015
Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational studyKarina Jahnz-Różyk, Paweł Szepiel
Postepy Higieny I Medycyny Doswiadczalnej (Online)|June 4, 2016
[Autoimmune connective tissue diseases and vaccination]Ewa Więsik-Szewczyk, Karina Jahnz-Różyk
Medicine|November 2, 2018
A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacementEwa Więsik-Szewczyk, Karina Jahnz-Różyk
World Journal of Clinical Cases|October 7, 2020
From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiencyEwa Więsik-Szewczyk, Karina Jahnz-Różyk
Reumatologia|December 18, 2019
Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome persisting to adulthood - an example of a diagnostic and therapeutic challengeEwa Więsik-Szewczyk, Beata Wolska-Kuśnierz, Karina Jahnz-Różyk
BMC Pulmonary Medicine|March 18, 2018
Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in PolandKarina Jahnz-Różyk, Joanna Lis, Marta Warchoł, et al.
Value in Health Regional Issues|October 28, 2017
Drug Policy in PolandKarina Jahnz-Różyk, Pawel Kawalec, Krzysztof Malinowski, et al.
Frontiers in Immunology|May 20, 2026
Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimizationMariusz Sikora, Marcin Ziętkiewicz, Karina Jahnz-Różyk, et al.
Journal of Asthma and Allergy|December 28, 2020
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life ObservationAleksandra Kucharczyk, Ewa Więsik-Szewczyk, Anna Poznańska, et al.
Pageof 6